Protagonist Therapeutics Inc

PTGX

Add to Watchlist

103.880USD

+3.930+3.93%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

Protagonist Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

65 / 383

Overall Ranking

183 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Protagonist Therapeutics Inc Highlights

StrengthsRisks

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Growing

The company is in a growing phase, with the latest annual income totaling USD 46.02M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 46.02M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -55.40, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 76.23M shares, decreasing 4.07% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 288.00 shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

117.583

Target Price

+18.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Protagonist Therapeutics Inc is 6.39, ranking 247 out of 383 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 56.37M, representing a year-over-year increase of 99.03%, while its net profit experienced a year-over-year increase of 132.46%.

Score

Industry at a Glance

Previous score

6.39

Change

0



Financials

8.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Protagonist Therapeutics Inc is 4.19, ranking 375 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -55.40, which is -321.60% below the recent high of 122.78 and -3.55% above the recent low of -57.37.

Score

Industry at a Glance

Previous score

4.19

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Protagonist Therapeutics Inc is 8.46, ranking 121 out of 383 in the Biotechnology & Medical Research industry. The average price target is 91.00, with a high of 115.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.46

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Protagonist Therapeutics Inc is 7.17, ranking 127 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 105.63 and the support level at 95.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

-1.98

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Protagonist Therapeutics Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 118.60%, representing a quarter-over-quarter decrease of 0.99%. The largest institutional shareholder is PRFDX, holding a total of 1.34M shares, representing 2.09% of shares outstanding, with 1.51% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.32M

+3.74%

Farallon Capital Management, L.L.C.

6.14M

-0.84%

UBS Financial Services, Inc.

2.77M

+46.12%

RTW Investments L.P.

5.06M

-12.11%

State Street Investment Management (US)

3.20M

+1.07%

Wellington Management Company, LLP

3.17M

+66.18%

Janus Henderson Investors

2.65M

+140.73%

Johnson & Johnson Innovation-JJDC, Inc.

2.45M

--

Geode Capital Management, L.L.C.

1.45M

+2.56%

Woodline Partners LP

1.41M

-2.05%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Protagonist Therapeutics Inc is 6.39, ranking 25 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 1.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Protagonist Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Protagonist Therapeutics Inc

PTGX

6.99 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment